[Clinical effects of dalitong granule combined proton pump inhibitors on gastroesophageal reflux disease].
To observe the clinical effects of Dalitong Granule (DG) combined proton pump inhibitors (PPI) on gastroesophageal reflux disease (GERD). Totally 186 patients with GERD were randomly assigned to three groups, i.e., the control group A (61 cases, only PPI group, Rabeprazole Capsule 20 mg, once daily), the control group B (61 cases, PPI with domperidone group, Rabeprazole 20 mg, once daily; Domperidone 10 mg each time, thrice daily), and the experimental group (64 cases, PPI + DG group, Rabeprazole 20 mg, once daily; DG, 6 g each time, thrice daily). The treatment lasted for 4 weeks for all. The symptom scoring, the overall efficacy, local efficacy, and adverse drug reactions were compared among the three groups before and after treatment. Totally 183 patients completed the experiment. After 4 weeks of treatment, the symptom scores in the three groups were significantly lowered. It was the lowest in the experimental group with statistical difference (P < 0.01). The markedly effective rate and the effective rate of the experimental group were significantly higher than those of the control A and B groups. The local markedly effective rate and the effective rate of the reflux esophagitis (RE) in the experimental group were significantly higher than those of the control A and B groups (P<0.05). No serious adverse reactions occurred in the three groups during the treatment period. DG combined PPI could improve the symptoms of GERD safely and effectively.